Monday, December 9, 2002

OncoLink attended the 44th Annual Meeting of the American Society of Hematology (ASH) from Philadelphia, Pennsylvania. OncoLink reporters provided in-depth, up-to-the-minute coverage of sessions and presentations.

OncoLink Booth setup at ASH

A Combination of Low Dose Thalidomide with Prednisone in Myelofibrosis with Myeloid Metaplasia Presenter: Ruben A. MesaPresenter's Affiliation: Mayo Clinic; Rochester, MNType of Session: ScientificBackground Myelofibriosis with Myeloid Metaplasia (MMM) is a clonal myeloproliferative disorder with varied prognosis and severity. A curative...
A Decision Analysis of Allogeneic Stem Cell Transplantation for MDS: Delayed Transplantation for Low Risk MDS Is Associated with Imporved Outcome Presenter: Corey CutlerPresenter's Affiliation: Dana Farber, Boston, MAType of Session: ReportingBackground Therapies for MDS are limited and unrewarding. Allogeneic transplants can provide cure for 25-40% of the pts. Low risk MDS pts have a life...
A Multicenter Randomized Trial of Fludarabine and Mitoxantrone (FM) Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma (FL) Presenter: Pier Luigi ZinzaniPresenter's Affiliation: Italian Cooperative Study Group on LymphomaType of Session: ScientificBackground Follicular lymphoma is a low grade lymphoma that typically has a smoldering disease course. Many patients progress...
Allogeneic Stem Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL) patients <50 years old in first complete remission(CR) A Donor vs no donor comparison in the EORTC ALL-3 Study. Presenter: Boris LabarPresenter's Affiliation: EORTCType of Session: ReportingBackground Allo transplant for ALL has been used for over 20 years but despite its' general application its role in adults remains unclear. The contraversy remains between...
Consolidation of AML Therapy with Autograft and Allograft Procedures Does not Negate the Poor Prognostic Impact of FLT-3 Internal Tandem Duplications: Results for UK MRC AML 10 and 12 Trials. Presenter: Panagiotis D. KottaridisPresenter's Affiliation: London, UKType of Session: ScientificBackground Currently >80% of AML pts over the age of 60 will attian a complete remission (CR). Those who receive post CR intensification therapy (either...
Effects of 40,000 IU Bi-Weekly (BIW) Induction Dose of Epoetin Alfa Followed by 40,000 IU Once Weekly (QW) in Low-Risk Myelodysplastic Syndrome (MDS) Patients. Presenter: Maria A. A. SpiritiPresenter's Affiliation: Italian Fatigue-QoL/MDS Cooperative Group, ItalyType of Session: PosterBackground Anemia is a serious problem in MDS and other hematologic malignancies. >50% of patients with MDS will have...
FDG-PET Is Superior to Gallium Scintigraphy in the Staging and Follow-Up of Patients with De Novo Hodgkin's Disease: a Prospective, Blinded Comparison Presenter: Jonathan W. FriedbergPresenter's Affiliation: University of RochesterType of Session: PosterBackground Accurate hodgkin's disease (HD) staging with CT scan and nuclear scintigraphy allows optimal treatment planning and prevents under or...
Gene Expression Profiles in AIDS-Related Lymphomas (ARL): Burkitt Lymphoma (BL) and Diffuse Large B-Cell Lymphoma-Immunoblastic Variant (DLBCL-IBL) Presenter: Sven de VosPresenter's Affiliation: UCLAType of Session: ScientificBackground Primary CNS lymphoma and other malignant lymphomas continue to be a large problem in patients with AIDS. The most common type of lymphoma in these patients...
Low Dose Decitabine for Elderly High Risk MDS Patients: Who Will Respond? Presenter: P.W. WijermansPresenter's Affiliation: The Hague; NethrelandsType of Session: ScientificBackground MDS is a rare disease with an inevitably fatal outcome. The treatment is cumbersome, especially in the elderly. Previous studies of...
N998B: Multicenter Phase II Trial of Thalidomide (Thal) in Adult Patients with Myelodysplastic Syndromes (MDS) Presenter: Alvaro Moreno-AspitiaPresenter's Affiliation: Mayo Clinic, Rochester, MNType of Session: ScientificBackground Bone Marrow specimens in patients with MDS have increased levels of the following cytokines: TNF-á, TGF-â, IL-1, and IFN-ã. Bone...
Radiotherapy is Unnecessary in Elderly Patients With Localized Aggressive Non-Hodgkin's Lymphoma: Results of the GELA LNH 93-4 Study Presenter: Georges FilletPresenter's Affiliation: Hematology, CHU - Sart TilmanType of Session: ScientificBackground CHOP plus local radiotherapy is considered the standard treatment for localized, aggressive Non-Hodgkin's Lymphoma (NHL). It has...
Superiority of Chemotherapy Alone with the ACVBP Regimen over Treatment with Three Cycles of CHOP Plus Radiotherapy in Low Risk Localized Aggressive Lymphoma: The LNH93-1 GELA Study Presenter: Felix ReyesPresenter's Affiliation: GELAType of Session: ScientificBackground Chemoradiation is likely the most common form of treatment in patients with aggressive but localized Non-Hodgkin's Disease (NHL). However, published series...
Treatment of Hypereosinophilic Syndrome (HES) with Imatinib Mesylate Presenter: Jorge E. CortesPresenter's Affiliation: M.D. Anderson Cancer Center; Houston, TXType of Session: ScientificBackground HES is a rare hematologic disorder characterized by persistent eosinophilia associated with organ involvement. The...
Treatment-Related Myelodysplastic Sydromes (t-MDS) after Autotransplants (AT) for Multiple Myeloma (MM) Presenter: Guido J. TricotPresenter's Affiliation: University of Arkansas for Medical Sciences; Little Rock, ARType of Session: ScientificBackground Overall Survival (OS) in Multiple Myeloma (MM) has increased with the recent onset of tandem...
Two Cycles ABVD Plus Extended Field Radiotherapy Is Superior to Radiotherapy Alone in Early Stage Hodgkin's Disease: Results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7 Presenter: Markus SieberPresenter's Affiliation: University of CologneType of Session: ScientificBackground Extended Field (EF)Radiotherapy alone has been considered the standard for early stage Hodgkin's Disease (HD) with 90% 10 year Overall...